Synthesis and Pharmacological Evaluation of Novel Adenine-Hydrogen Sulfide Slow Release Hybrids Designed as Multitarget Cardioprotective Agents

Nikolaos Lougiakis, Andreas Papapetropoulos, Evangelos Gikas, Spyridon Toumpas, Panagiotis Efentakis, Rudolf Wedmann, Anastasia Zoga, Zhongmin Zhou, Efstathios K. Iliodromitis, Alexios Leandros Skaltsounis, Milos R. Filipovic, Nicole Pouli, Panagiotis Marakos, Ioanna Andreadou

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

This work deals with the design, synthesis, and evaluation of the cardioprotective properties of a number of novel hybrid compounds combining the adenine nucleus with a suitable H2S slow-releasing moiety, coupled via a stable ether bond. The H2S release rate of the hybrids and their ability to increase cGMP were estimated in vitro. The most promising derivatives 4 and 11, both containing 4-hydroxythiobenzamide moiety as H2S donor, were selected for further in vivo evaluation. Their ability to release H2S in vivo was recorded using a new fully validated UPLC-DAD method. Both compounds reduced significantly the infarct size when administered at the end of sustained ischemia. Mechanistic studies showed that they conferred enhanced cardioprotection compared to adenine or 4-hydroxythiobenzamide. They activate the PKG/PLN pathway in the ischemic myocardium, suggesting that the combination of both pharmacophores results in synergistic cardioprotective activity through the combination of both molecular pathways that trigger cardioprotection.

Original languageEnglish (US)
Pages (from-to)1776-1790
Number of pages15
JournalJournal of Medicinal Chemistry
Volume59
Issue number5
DOIs
StatePublished - Mar 10 2016
Externally publishedYes

Fingerprint

Cardiotonic Agents
Hydrogen Sulfide
Adenine
Pharmacology
Ether
Myocardium
Ischemia
In Vitro Techniques

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Synthesis and Pharmacological Evaluation of Novel Adenine-Hydrogen Sulfide Slow Release Hybrids Designed as Multitarget Cardioprotective Agents. / Lougiakis, Nikolaos; Papapetropoulos, Andreas; Gikas, Evangelos; Toumpas, Spyridon; Efentakis, Panagiotis; Wedmann, Rudolf; Zoga, Anastasia; Zhou, Zhongmin; Iliodromitis, Efstathios K.; Skaltsounis, Alexios Leandros; Filipovic, Milos R.; Pouli, Nicole; Marakos, Panagiotis; Andreadou, Ioanna.

In: Journal of Medicinal Chemistry, Vol. 59, No. 5, 10.03.2016, p. 1776-1790.

Research output: Contribution to journalArticle

Lougiakis, N, Papapetropoulos, A, Gikas, E, Toumpas, S, Efentakis, P, Wedmann, R, Zoga, A, Zhou, Z, Iliodromitis, EK, Skaltsounis, AL, Filipovic, MR, Pouli, N, Marakos, P & Andreadou, I 2016, 'Synthesis and Pharmacological Evaluation of Novel Adenine-Hydrogen Sulfide Slow Release Hybrids Designed as Multitarget Cardioprotective Agents', Journal of Medicinal Chemistry, vol. 59, no. 5, pp. 1776-1790. https://doi.org/10.1021/acs.jmedchem.5b01223
Lougiakis, Nikolaos ; Papapetropoulos, Andreas ; Gikas, Evangelos ; Toumpas, Spyridon ; Efentakis, Panagiotis ; Wedmann, Rudolf ; Zoga, Anastasia ; Zhou, Zhongmin ; Iliodromitis, Efstathios K. ; Skaltsounis, Alexios Leandros ; Filipovic, Milos R. ; Pouli, Nicole ; Marakos, Panagiotis ; Andreadou, Ioanna. / Synthesis and Pharmacological Evaluation of Novel Adenine-Hydrogen Sulfide Slow Release Hybrids Designed as Multitarget Cardioprotective Agents. In: Journal of Medicinal Chemistry. 2016 ; Vol. 59, No. 5. pp. 1776-1790.
@article{15bacd5586b947fb920ab7a5638a9bbc,
title = "Synthesis and Pharmacological Evaluation of Novel Adenine-Hydrogen Sulfide Slow Release Hybrids Designed as Multitarget Cardioprotective Agents",
abstract = "This work deals with the design, synthesis, and evaluation of the cardioprotective properties of a number of novel hybrid compounds combining the adenine nucleus with a suitable H2S slow-releasing moiety, coupled via a stable ether bond. The H2S release rate of the hybrids and their ability to increase cGMP were estimated in vitro. The most promising derivatives 4 and 11, both containing 4-hydroxythiobenzamide moiety as H2S donor, were selected for further in vivo evaluation. Their ability to release H2S in vivo was recorded using a new fully validated UPLC-DAD method. Both compounds reduced significantly the infarct size when administered at the end of sustained ischemia. Mechanistic studies showed that they conferred enhanced cardioprotection compared to adenine or 4-hydroxythiobenzamide. They activate the PKG/PLN pathway in the ischemic myocardium, suggesting that the combination of both pharmacophores results in synergistic cardioprotective activity through the combination of both molecular pathways that trigger cardioprotection.",
author = "Nikolaos Lougiakis and Andreas Papapetropoulos and Evangelos Gikas and Spyridon Toumpas and Panagiotis Efentakis and Rudolf Wedmann and Anastasia Zoga and Zhongmin Zhou and Iliodromitis, {Efstathios K.} and Skaltsounis, {Alexios Leandros} and Filipovic, {Milos R.} and Nicole Pouli and Panagiotis Marakos and Ioanna Andreadou",
year = "2016",
month = "3",
day = "10",
doi = "10.1021/acs.jmedchem.5b01223",
language = "English (US)",
volume = "59",
pages = "1776--1790",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - Synthesis and Pharmacological Evaluation of Novel Adenine-Hydrogen Sulfide Slow Release Hybrids Designed as Multitarget Cardioprotective Agents

AU - Lougiakis, Nikolaos

AU - Papapetropoulos, Andreas

AU - Gikas, Evangelos

AU - Toumpas, Spyridon

AU - Efentakis, Panagiotis

AU - Wedmann, Rudolf

AU - Zoga, Anastasia

AU - Zhou, Zhongmin

AU - Iliodromitis, Efstathios K.

AU - Skaltsounis, Alexios Leandros

AU - Filipovic, Milos R.

AU - Pouli, Nicole

AU - Marakos, Panagiotis

AU - Andreadou, Ioanna

PY - 2016/3/10

Y1 - 2016/3/10

N2 - This work deals with the design, synthesis, and evaluation of the cardioprotective properties of a number of novel hybrid compounds combining the adenine nucleus with a suitable H2S slow-releasing moiety, coupled via a stable ether bond. The H2S release rate of the hybrids and their ability to increase cGMP were estimated in vitro. The most promising derivatives 4 and 11, both containing 4-hydroxythiobenzamide moiety as H2S donor, were selected for further in vivo evaluation. Their ability to release H2S in vivo was recorded using a new fully validated UPLC-DAD method. Both compounds reduced significantly the infarct size when administered at the end of sustained ischemia. Mechanistic studies showed that they conferred enhanced cardioprotection compared to adenine or 4-hydroxythiobenzamide. They activate the PKG/PLN pathway in the ischemic myocardium, suggesting that the combination of both pharmacophores results in synergistic cardioprotective activity through the combination of both molecular pathways that trigger cardioprotection.

AB - This work deals with the design, synthesis, and evaluation of the cardioprotective properties of a number of novel hybrid compounds combining the adenine nucleus with a suitable H2S slow-releasing moiety, coupled via a stable ether bond. The H2S release rate of the hybrids and their ability to increase cGMP were estimated in vitro. The most promising derivatives 4 and 11, both containing 4-hydroxythiobenzamide moiety as H2S donor, were selected for further in vivo evaluation. Their ability to release H2S in vivo was recorded using a new fully validated UPLC-DAD method. Both compounds reduced significantly the infarct size when administered at the end of sustained ischemia. Mechanistic studies showed that they conferred enhanced cardioprotection compared to adenine or 4-hydroxythiobenzamide. They activate the PKG/PLN pathway in the ischemic myocardium, suggesting that the combination of both pharmacophores results in synergistic cardioprotective activity through the combination of both molecular pathways that trigger cardioprotection.

UR - http://www.scopus.com/inward/record.url?scp=84960913426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960913426&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.5b01223

DO - 10.1021/acs.jmedchem.5b01223

M3 - Article

VL - 59

SP - 1776

EP - 1790

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 5

ER -